Osteosarcoma and teriparatide?

Journal of Bone and Mineral Research

Volumn 22, Issue 2, 2007, Pages 334-

  Harper, Kristine D ^a   Krege, John H ^a   Marcus, Robert ^a   Mitlak, Bruce H ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PARATHYROID HORMONE[1-34];

AGED; CASE REPORT; DIFFERENTIAL DIAGNOSIS; FEMALE; HISTOPATHOLOGY; HUMAN; LETTER; LUNG CANCER; MEDICAL LITERATURE; METASTASIS; OSTEOSARCOMA;

BONE NEOPLASMS; FEMALE; HUMANS; OSTEOSARCOMA; TERIPARATIDE;

EID: 33846543133     PISSN: 08840431     EISSN: None     Source Type: Journal    
DOI: 10.1359/jbmr.061111     Document Type: Letter

References (6)

1. Gold DT, Pantos BS, Masica DN, Misurski DA, Marcus R 2006 Initial experience with teriparatide in the United States. Curr Med Res Opin 22:703-708.
2. Tashjian AH Jr, Gagel RF 2006 Teriparatide [human PTH(1-34)]: 2.5 years of experience on the use and safety of the drug for the treatment of osteoporosis. J Bone Miner Res 21:354-365.
3. Vahle JL, Sato M, Long GG, Young JK, Francis PC, Engelhardt JA, Westmore M, Ma L, Nold JB 2002 Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone(1-34) for 2 years and relevance to human safety. Toxicol Pathol 30:312-321.
4. Vahle JL, Long GG, Sandusky G, Westmore M, Ma YL, Sato M 2004 Bone neoplasms in F344 rats given teriparatide [rhPTH(1-34)] are dependent on duration of treatment and dose. Toxicol Pathol 32:426-438.
5. Tashjian AH Jr, Chabner BA 2002 Commentary on clinical safety of recombinant human parathyroid hormone 1-34 in the treatment of osteoporosis in men and postmenopausal women. J Bone Miner Res 17:1151-1161.
6. Surveillance Research Program National Cancer Institute SEER*Stat Software, version 6.1.4. Available at www.seer. cancer.gov/seerstat.